207 related articles for article (PubMed ID: 10668939)
1. The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.
Kondás J; Kiss L; Határ A; Kiss A; Lukács T; Szeldeli P; Törzsök F; Bodrogi I
Int Urol Nephrol; 1999; 31(4):451-6. PubMed ID: 10668939
[TBL] [Abstract][Full Text] [Related]
2. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
3. Repeat transurethral resection lowers recurrence rates in T1 bladder tumors, even after intravesical mitomycin C.
Oosterlinck W
Nat Clin Pract Urol; 2006 Nov; 3(11):582-3. PubMed ID: 17088923
[No Abstract] [Full Text] [Related]
4. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
5. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
6. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.
Tolley DA; Parmar MK; Grigor KM; Lallemand G; Benyon LL; Fellows J; Freedman LS; Grigor KM; Hall RR; Hargreave TB; Munson K; Newling DW; Richards B; Robinson MR; Rose MB; Smith PH; Williams JL; Whelan P
J Urol; 1996 Apr; 155(4):1233-8. PubMed ID: 8632538
[TBL] [Abstract][Full Text] [Related]
7. Short schedule intravesical mitomycin preceding transurethral resection for recurrent Ta-T1, G1-G2 bladder cancer.
Maffezzini M; Simonato A; Lodolo C; Raber M; Carmignani G
Tumori; 1995; 81(3):191-3. PubMed ID: 7571026
[TBL] [Abstract][Full Text] [Related]
8. Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin C: 48-month follow-up.
Minervini R; Felipetto R; Viganò L; Pampaloni S; Fiorentini L
Urol Int; 1996; 56(4):234-7. PubMed ID: 8776821
[TBL] [Abstract][Full Text] [Related]
9. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.
Saika T; Tsushima T; Nasu Y; Miyaji Y; Saegusa M; Takeda K; Kumon H
World J Urol; 2010 Aug; 28(4):413-8. PubMed ID: 20054553
[TBL] [Abstract][Full Text] [Related]
10. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
11. [Intravesical instillation in the treatment of superficial tumors of the bladder].
Chopin DK
Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
[TBL] [Abstract][Full Text] [Related]
12. Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group.
Bono AV; Hall RR; Denis L; Lovisolo JA; Sylvester R
Eur Urol; 1996; 29(4):385-90. PubMed ID: 8791042
[TBL] [Abstract][Full Text] [Related]
13. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
Witjes JA; Caris CT; Mungan NA; Debruyne FM; Witjes WP
J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
[TBL] [Abstract][Full Text] [Related]
14. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
Lindgren MS; Bue P; Azawi N; Blichert-Refsgaard L; Sundelin MO; Dyrskjøt L; Jensen JB
Eur Urol; 2020 Dec; 78(6):856-862. PubMed ID: 32736928
[TBL] [Abstract][Full Text] [Related]
15. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
[TBL] [Abstract][Full Text] [Related]
16. Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor.
Onishi T; Sasaki T; Hoshina A; Yabana T
Anticancer Res; 2011 Apr; 31(4):1471-4. PubMed ID: 21508405
[TBL] [Abstract][Full Text] [Related]
17. 4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.
da Silva FC; Ferrito F; Brandão T; Santos A
Eur Urol; 1992; 21(1):42-4. PubMed ID: 1606981
[TBL] [Abstract][Full Text] [Related]
18. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
[TBL] [Abstract][Full Text] [Related]
19. Intravesical mitomycin C for superficial transitional cell carcinoma.
Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
[TBL] [Abstract][Full Text] [Related]
20. [Management of non invasive bladder cancers. T1Ga urothelial cell carcinoma: benefit of immediate post operative instillation?].
Rouprêt M; Guillotreau J; Irani J; Zerbib M
Prog Urol; 2010 Mar; 20 Suppl 1():S46-9. PubMed ID: 20493444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
